|
||
| |||||||
|
Introduction: For five decades, the oncology pharmaceuticals market has been dominated by cytotoxic therapies, used alone or in combinations. In 2002, however, this dominance began to be challenged by improved molecular biology techniques and the niche positioning of biotechnology companies specializing in rational drug design. Scope: * Discussion of the role niche cancers are assuming in the oncology market as of 2002 * Strategy-oriented discussion of lifecycle strategies being employed by selected maturing or emerging high-profile oncology drugs * Predictions for changes in the clinical trials design process to accommodate the mechanism of action of novel molecular-based products Report Highlights: Niche cancers are beginning to receive as much attention for new drug development as has long been enjoyed by major cancers, with indications such as leukemia and multiple myeloma attracting investment and research resources Aggressive marketing can extend the lifespan of commercialized agents, but competition from generics and replacement products means that few drugs can maintain blockbuster sales in the oncology field for more than a few years, based on the experiences of 2002 Pipeline agents from novel classes are eagerly awaited but face the challenges of proving themselves more effective than a plethora of established agents, despite difficulties in clinical trial design Reasons to Purchase: * Identify market trends from 2002, and predict their impact on the market in 2003 * Understand the importance of niche cancers in the development of oncology portfolios * Track the development of clinical trial design, as novel drugs enter clinical trials Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a273 |
|
|
